HIPPOCRATES® project: A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting

Table 2 Laboratory data in the beginning of the treatment

Laboratory data	Median (IQR)
Hemoglobin, g/dL	15.7 (14.9-16.0)
Leukocytes, × 109/L	7.9 (7.0-10.2)
Platelets, × 109/L	204.5 (175.8-238.8)
Albumin, g/dL	58.4 (55.0-61.1)
AST, U/L	36.0 (28.0-47.8)
ALT, U/L	47.0 (31.0-67.0)
GGT, U/L	41.5 (27.0-72.0)
Alkaline phosphatase, U/L	76.5 (65.5-94.5)
Total bilirubin, mg/dL	0.48 (0.32-0.6)
Total cholesterol, mg/dL	162.0 (142.0-200.0)
Alpha-fetoprotein, ng/mL	2.0 (1.4-3.5)
Creatinine, mg/dL	0.8 (0.7-0.9)
INR	1.0 (1.0-1.1)
Anti-HBc antibody+	41 (41.8%)
Anti-HBs antibody+	33 (33.7%)

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: γ-glutamyl transpeptidase; IQR: Interquartile range.